ESMO

Views & Analysis

At ESMO 2022, oncologists saw exciting cancer advances

Lung, breast, and non-prostate genitourinary (NGU) cancer treatments were the most exciting tracks due to the march towards personalised medicine and expanded immunotherapy options.

Oncology

At ESMO, three studies show promise of antibody-drug conjuga...

The American Society of Clinical Oncology, or ASCO, conference is just around the corner, but one subgroup of cancer researchers just had their own gathering, as breast cancer researchers c

News

ESMO21: Enhertu brings it’s A game to second-line breast can...

AstraZeneca and Daiichi Sankyo were clearly excited by data from a trial pitting their HER2 antibody-drug conjugate (ADC) Enhertu against Roche's rival Kadcyla when they reported top-line r

News

ESMO21: First combo data with Amgen's Lumakras hit the mark ...

Amgen has made progress with its plans to expand the use of its first-in-class KRAS inhibitor Lumakras, reporting encouraging results when the drug is used alongside its EGFR drug Vectibix

News

ESMO21: Roche's giredestrant takes stage in battle of the or...

Roche has revealed the first phase 2 clinical data with giredestrant, one of a clutch of new selective oestrogen receptor degraders (SERDs) hoping to provide an oral alternative to AstraZen

News